Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly.
British Journal of Cancer (2006) 95, 197–203. doi:10.1038/sj.bjc.6603236 www.bjcancer.com
Published online 27 June 2006
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
- 1Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid 28040, Spain
- 2Department of Neurosurgery, Hospital Universitario de Canarias, La Laguna, Tenerife 38320, Spain